Emerging Markets Earnings: Strong Showing For Bayer Despite China Nexavar Hiccup
This article was originally published in PharmAsia News
Executive Summary
Bayer slowly but surely nears the halfway mark for the proportion of overall sales from emerging markets with double-digit growth in the third quarter, though the company faced some hiccups related to Nexavar stocks in China